ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2019

Strong sales growth during October; Zinzino group revenue increased with a total of 52% compared with the previous year.

The revenue in October for Zinzino's sales markets increased by 55% to MSEK 84.1 (54.1) due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 3% and amounted to MSEK 4.2 (4.1). Overall the Group increased revenues by 52% to MSEK 88.3 (58.2) compared with the previous year.

Accumulated revenue for January – October 2019 increased by 30% MSEK 622.62 (479.1).

Revenues distributed as follows:

  
The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
email: certifiedadviser@penser.se

 
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 3:15pm the 11th of November 2019.

Zinzino AB (publ.) is a direct sales company that operates throughout Europe, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActie Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 34 markets across Europe, North America and Australia. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public company listed on Nasdaq First North.